Form 4: Replimune CEO Receives Major Equity Incentive Grants

Replimune Group CEO Sushil Patel has been granted over 600,000 shares and options as part of a long-term incentive package.

Summary

• Chief Executive Officer Sushil Patel received a grant of 251,240 Restricted Stock Units (RSUs) on April 1, 2026.
• Patel also received 376,860 employee stock options with an exercise price of $7.61 per share.
• The RSUs follow a four-year vesting schedule, with the first 25% vesting on May 15, 2027, and the remainder in annual installments through 2030.
• The stock options vest over four years, with 25% vesting on April 1, 2027, followed by 36 monthly installments.
• Following these transactions, Patel directly owns 784,816 shares of common stock and 376,860 derivative securities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as slightly positive due to the strong long-term incentive alignment for the CEO, though the administrative filing delay and potential dilution are minor points of caution.

Positives

• Strong alignment of interest between the CEO and shareholders through significant equity ownership.
• Long-term vesting schedules (up to 2030) encourage executive retention and long-term strategic focus.
• The exercise price of $7.61 sets a clear benchmark for value creation for the option component.

Negatives

• The issuance of 628,100 total underlying shares represents potential future dilution for existing shareholders.
• The filing was submitted late due to an administrative error, which may indicate minor lapses in internal compliance tracking.

Risks

• Dilution risk as the 628,100 shares and options are eventually issued or exercised.
• The stock options only provide value if the share price exceeds the $7.61 exercise price, creating a risk of zero-value compensation if the company underperforms.
• Heavy reliance on the CEO, as evidenced by the substantial incentive package designed to retain his services through 2030.

Future Outlook

The long-term vesting structure suggests that management is focused on a multi-year growth trajectory, with full realization of these incentives not occurring until 2030.

Management Comments

• This Form 4 is being filed late due to inadvertent administrative error.

Industry Context

StockSavvy.ai notes that in the biotechnology sector, high-equity compensation for CEOs is standard practice to conserve cash while aligning leadership with the long timelines required for clinical development and regulatory approval.

Comparison to Industry Standards

• The four-year vesting period is consistent with standard executive compensation packages in the Nasdaq Biotechnology Index.
• The grant size is typical for a mid-cap biotech CEO, balancing performance incentives with retention.
• The use of both RSUs and options is a common 'balanced' approach to executive equity in the healthcare sector.

Corporate Governance

Related Party Transactions

• Grant of 251,240 RSUs and 376,860 stock options to CEO Sushil Patel as part of compensation.

Stakeholder Impact

• Shareholders: Potential dilution of approximately 628,100 shares over the next four years.
• Management: CEO is heavily incentivized to increase share price above $7.61.

Next Steps

• Monitor for similar grants to other key executives which may follow this cycle.
• Track the company's progress toward the May 2027 initial vesting milestone.

Key Dates

Recommendation

This is a routine compensation event that confirms the CEO's long-term commitment to the company but does not provide new material information regarding the company's clinical pipeline or financial health.

Keywords

Replimune Group, REPL, Sushil Patel, CEO Compensation, Stock Options, Restricted Stock Units, Insider Ownership, Biotechnology, Equity Grant